{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T21:35:13Z","timestamp":1790285713083,"version":"4.1.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,6,4]],"date-time":"2020-06-04T00:00:00Z","timestamp":1591228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,4]],"date-time":"2020-06-04T00:00:00Z","timestamp":1591228800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Gynecol Obstet"],"published-print":{"date-parts":[[2020,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>In pregnant women with a history of fetal and neonatal alloimmune thrombocytopenia (FNAIT), prenatal intervention in subsequent pregnancies may be required to prevent fetal bleeding. Several invasive and non-invasive protocols have been published: amniocentesis for fetal genotyping, fetal blood sampling for the determination of fetal platelet count, intrauterine platelet transfusions, and weekly maternal i.v. immunoglobulin (IVIG) infusion with or without additional corticosteroid therapy. This is the first retrospective study that report the experience with a non-invasive protocol focused on side effects of maternal IVIG treatment and neonatal outcome.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Pregnant women with proven FNAIT in history and an antigen positive fetus were treated with IVIG (1\u00a0g\/kg\/bw) every week. To identify potential IVIG-related hemolytic reactions isoagglutinin titer of each IVIG lot and maternal blood count were controlled. IVIG-related side effects were prospectively documented and evaluated. Furthermore, ultrasound examination of the fetus was performed before starting IVIG administration and continued regularly during treatment. Outcome of the index and subsequent pregnancy was compared. Corresponding data of the newborns were analyzed simultaneously.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      IVIG was started at 20\u00a0weeks of gestation (median). Compared to the index pregnancy, platelet counts of the newborns were higher in all cases. No intracranial hemorrhage occurred (Index pregnancies: 1 case). Platelet counts were 187\u00a0\u00d7\u00a010\n                      <jats:sup>9<\/jats:sup>\n                      \/l (median, range 22\u2013239, 95% CI) and one newborn had mild bleeding. No severe hemolytic reaction was observed and side effects were moderate.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Among pregnant women with FNAIT history, the use of non-invasive fetal risk determination and maternal IVIG resulted in favorite outcome of all newborns. Invasive diagnostic or therapeutic procedures in women with a history of FNAIT should be abandoned.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00404-020-05618-y","type":"journal-article","created":{"date-parts":[[2020,6,3]],"date-time":"2020-06-03T20:02:21Z","timestamp":1591214541000},"page":"355-363","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Non-invasive risk-assessment and bleeding prophylaxis with IVIG in pregnant women with a history of fetal and neonatal alloimmune thrombocytopenia: management to minimize adverse events"],"prefix":"10.1007","volume":"302","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6403-0714","authenticated-orcid":false,"given":"Sandra","family":"Wienzek-Lischka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelika","family":"Sawazki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harald","family":"Ehrhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich J.","family":"Sachs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Axt-Fliedner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregor","family":"Bein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,4]]},"reference":[{"key":"5618_CR1","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1111\/j.1538-7836.2009.03380.x","volume":"7","author":"J Bussel","year":"2009","unstructured":"Bussel J (2009) Diagnosis and management of the fetus and neonate with alloimmune thrombocytopenia. J Thromb Haemost 7:253\u2013257. https:\/\/doi.org\/10.1111\/j.1538-7836.2009.03380.x","journal-title":"J Thromb Haemost"},{"issue":"1","key":"5618_CR2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/bjh.12235","volume":"161","author":"JA Peterson","year":"2013","unstructured":"Peterson JA, McFarland JG, Curtis BR et al (2013) Neonatal alloimmune thrombocytopenia: pathogenesis, diagnosis and management. Br J Haematol 161(1):3\u201314. https:\/\/doi.org\/10.1111\/bjh.12235","journal-title":"Br J Haematol"},{"issue":"5","key":"5618_CR3","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1111\/1471-0528.13343","volume":"123","author":"H Tiller","year":"2016","unstructured":"Tiller H, Husebekk A, Skogen B et al (2016) True risk of fetal\/neonatal alloimmune thrombocytopenia in subsequent pregnancies: a prospective observational follow-up study. Int J Obstet Gynecol 123(5):738\u2013744. https:\/\/doi.org\/10.1111\/1471-0528.13343","journal-title":"Int J Obstet Gynecol"},{"issue":"3","key":"5618_CR4","doi-asserted-by":"publisher","first-page":"e002490","DOI":"10.1136\/bmjopen-2012-002490","volume":"3","author":"H Tiller","year":"2013","unstructured":"Tiller H, Kamphuis MM, Flodmark O et al (2013) Fetal intracranial haemorrhages caused by fetal and neonatal alloimmune thrombocytopenia: an observational cohort study of 43 cases from an international multicentre registry. BMJ Open 3(3):e002490. https:\/\/doi.org\/10.1136\/bmjopen-2012-002490","journal-title":"BMJ Open"},{"issue":"11","key":"5618_CR5","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1182\/blood-2016-10-739656","volume":"129","author":"D Winkelhorst","year":"2017","unstructured":"Winkelhorst D, Murphy MF, Greinacher A et al (2017) Antenatal management in fetal and neonatal alloimmune thrombocytopenia: a systematic review. Blood 129(11):1538\u20131547","journal-title":"Blood"},{"issue":"4","key":"5618_CR6","doi-asserted-by":"publisher","first-page":"471.e1","DOI":"10.1016\/j.ajog.2016.04.033","volume":"215","author":"M Lakkaraja","year":"2016","unstructured":"Lakkaraja M, Berkowitz RL, Vinograd CA et al (2016) Omission of fetal sampling in treatment of subsequent pregnancies in fetal-neonatal alloimmune thrombocytopenia. Am J Obstet Gynecol 215(4):471.e1\u2013471.e9. https:\/\/doi.org\/10.1016\/j.ajog.2016.04.033","journal-title":"Am J Obstet Gynecol"},{"issue":"6pt2","key":"5618_CR7","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1111\/trf.13102","volume":"55","author":"S Wienzek-Lischka","year":"2015","unstructured":"Wienzek-Lischka S, Krautwurst A, Fr\u00f6hner V et al (2015) Noninvasive fetal genotyping of human platelet antigen-1a using targeted massively parallel sequencing. Transfusion 55(6pt2):1538\u20131544. https:\/\/doi.org\/10.1111\/trf.13102","journal-title":"Transfusion"},{"issue":"4","key":"5618_CR8","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1067\/mob.2002.122140","volume":"186","author":"TG Overton","year":"2002","unstructured":"Overton TG, Duncan KR, Jolly M et al (2002) Serial aggressive platelet transfusion for fetal alloimmune thrombocytopenia: platelet dynamics and perinatal outcome. Am J Obstet Gynecol 186(4):826\u2013831. https:\/\/doi.org\/10.1067\/mob.2002.122140","journal-title":"Am J Obstet Gynecol"},{"key":"5618_CR9","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1056\/NEJM198811243192103","volume":"319","author":"JB Bussel","year":"1988","unstructured":"Bussel JB, Berkowitz RL, McFarland JG et al (1988) Antenatal treatment of neonatal alloimmune thrombocytopenia. N Engl J Med 319:1374\u20131378","journal-title":"N Engl J Med"},{"issue":"11","key":"5618_CR10","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.3324\/haematol.2010.025106","volume":"95","author":"G Giers","year":"2010","unstructured":"Giers G, Wenzel F, Stockschlader M et al (2010) Fetal alloimmune thrombocytopenia and maternal intravenous immunoglobulin infusion. Haematologica 95(11):1921\u20131926. https:\/\/doi.org\/10.3324\/haematol.2010.025106","journal-title":"Haematologica"},{"issue":"4","key":"5618_CR11","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1111\/j.1471-0528.2007.01244.x","volume":"114","author":"ESA van den Akker","year":"2007","unstructured":"van den Akker ESA, Oepkes D, Lopriore E et al (2007) Noninvasive antenatal management of fetal and neonatal alloimmune thrombocytopenia: safe and effective. BJOG Int J Obstet Gynaecol 114(4):469\u2013473. https:\/\/doi.org\/10.1111\/j.1471-0528.2007.01244.x","journal-title":"BJOG Int J Obstet Gynaecol"},{"issue":"11","key":"5618_CR12","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1111\/j.1471-0528.2010.02657.x","volume":"117","author":"MM Kamphuis","year":"2010","unstructured":"Kamphuis MM, Paridaans N, Porcelijn L et al (2010) Screening in pregnancy for fetal or neonatal alloimmune thrombocytopenia: systematic review. BJOG 117(11):1335\u20131343. https:\/\/doi.org\/10.1111\/j.1471-0528.2010.02657.x","journal-title":"BJOG"},{"issue":"05","key":"5618_CR13","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1055\/s-0033-1335685","volume":"34","author":"C K\u00e4hler","year":"2013","unstructured":"K\u00e4hler C, Gembruch U, Heling K-S et al (2013) Empfehlungen der DEGUM zur Durchf\u00fchrung von Amniozentese und Chorionzottenbiopsie. Ultraschall Med 34(05):435\u2013440. https:\/\/doi.org\/10.1055\/s-0033-1335685","journal-title":"Ultraschall Med"},{"issue":"S2","key":"5618_CR14","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.1111\/trf.13113","volume":"55","author":"CL Bellac","year":"2015","unstructured":"Bellac CL, Hottiger T, Jutzi MP et al (2015) The role of isoagglutinins in intravenous immunoglobulin-related hemolysis. Transfusion 55(S2):S13\u2013S22. https:\/\/doi.org\/10.1111\/trf.13113","journal-title":"Transfusion"},{"key":"5618_CR15","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1097\/AOG.0b013e3182765c63","volume":"121","author":"BD Rink","year":"2013","unstructured":"Rink BD, Gonik B, Chmait RH, O\u2019Shaughnessy R (2013) Maternal hemolysis after intravenous immunoglobulin treatment in fetal and neonatal alloimmune thrombocytopenia. Obstet Gynecol 121:471\u2013473","journal-title":"Obstet Gynecol"},{"issue":"03","key":"5618_CR16","doi-asserted-by":"publisher","first-page":"e197","DOI":"10.1055\/s-0037-1607055","volume":"07","author":"A Herrmann","year":"2017","unstructured":"Herrmann A, Samelson-Jones B, Brake S et al (2017) IVIG-associated maternal pancytopenia during treatment for neonatal alloimmune thrombocytopenia. AJP Rep 07(03):e197\u2013e200. https:\/\/doi.org\/10.1055\/s-0037-1607055","journal-title":"AJP Rep"},{"issue":"10","key":"5618_CR17","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.1111\/trf.13779","volume":"56","author":"M Lakkaraja","year":"2016","unstructured":"Lakkaraja M, Jin JC, Manotas KC et al (2016) Blood group A mothers are more likely to develop anemia during antenatal intravenous immunoglobulin treatment of fetal and neonatal alloimmune thrombocytopenia. Transfusion 56(10):2449\u20132454. https:\/\/doi.org\/10.1111\/trf.13779","journal-title":"Transfusion"},{"issue":"4","key":"5618_CR18","doi-asserted-by":"publisher","first-page":"211","DOI":"10.2165\/11537660-000000000-00000","volume":"24","author":"P Cherin","year":"2010","unstructured":"Cherin P, Cabane J (2010) Relevant criteria for selecting an intravenous immunoglobulin preparation for clinical use. Biodrugs 24(4):211\u2013223","journal-title":"Biodrugs"},{"issue":"11","key":"5618_CR19","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.3109\/14767058.2015.1063607","volume":"29","author":"KQ Rossi","year":"2016","unstructured":"Rossi KQ, Lehman KJ, O\u2019Shaughnessy RW (2016) Effects of antepartum therapy for fetal alloimmune thrombocytopenia on maternal lifestyle. J Matern Fetal Neonatal Med 29(11):1783\u20131788. https:\/\/doi.org\/10.3109\/14767058.2015.1063607","journal-title":"J Matern Fetal Neonatal Med"},{"issue":"2","key":"5618_CR20","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1159\/000380907","volume":"38","author":"NP Paridaans","year":"2015","unstructured":"Paridaans NP, Kamphuis MM, Taune Wikman A et al (2015) Low-dose versus standard-dose intravenous immunoglobulin to prevent fetal intracranial hemorrhage in fetal and neonatal alloimmune thrombocytopenia: a randomized trial. Fetal Diagn Ther 38(2):147\u2013153. https:\/\/doi.org\/10.1159\/000380907","journal-title":"Fetal Diagn Ther"},{"key":"5618_CR21","first-page":"66","volume":"13","author":"NM van der Lugt","year":"2015","unstructured":"van der Lugt NM, Kamphuis MM, Paridaans NPM et al (2015) Neonatal outcome in alloimmune thrombocytopenia after maternal treatment with intravenous immunoglobulin. Blood Transfus 13:66\u201371","journal-title":"Blood Transfus"},{"issue":"1","key":"5618_CR22","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.earlhumdev.2004.05.007","volume":"80","author":"CM Radder","year":"2004","unstructured":"Radder CM, de Haan Monique JJ, Brand A et al (2004) Follow up of children after antenatal treatment for alloimmune thrombocytopenia. Early Hum Dev 80(1):65\u201376. https:\/\/doi.org\/10.1016\/j.earlhumdev.2004.05.007","journal-title":"Early Hum Dev"},{"issue":"7","key":"5618_CR23","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1111\/j.1471-0528.2006.00993.x","volume":"113","author":"ESA van den Akker","year":"2006","unstructured":"van den Akker ESA, Oepkes D, Brand A et al (2006) Vaginal delivery for fetuses at risk of alloimmune thrombocytopenia? BJOG Int J Obstet Gynecol 113(7):781\u2013783. https:\/\/doi.org\/10.1111\/j.1471-0528.2006.00993.x","journal-title":"BJOG Int J Obstet Gynecol"},{"issue":"5","key":"5618_CR24","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1097\/AOG.0b013e31823403f4","volume":"118","author":"LD Pacheco","year":"2011","unstructured":"Pacheco LD, Berkowitz RL, Moise KJ et al (2011) Fetal and neonatal alloimmune thrombocytopenia. Obstet Gynecol 118(5):1157\u20131163. https:\/\/doi.org\/10.1097\/AOG.0b013e31823403f4","journal-title":"Obstet Gynecol"},{"issue":"3","key":"5618_CR25","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1111\/bjh.15813","volume":"185","author":"L Lieberman","year":"2019","unstructured":"Lieberman L, Greinacher A, Murphy MF et al (2019) Fetal and neonatal alloimmune thrombocytopenia: recommendations for evidence-based practice, an international approach. Br J Haematol 185(3):549\u2013562. https:\/\/doi.org\/10.1111\/bjh.15813","journal-title":"Br J Haematol"},{"key":"5618_CR26","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/985646","author":"P Palmeira","year":"2012","unstructured":"Palmeira P, Quinello C, Silveira-Lessa AL et al (2012) IgG placental transfer in healthy and pathological pregnancies. Clin Dev Immunol. https:\/\/doi.org\/10.1155\/2012\/985646","journal-title":"Clin Dev Immunol"}],"container-title":["Archives of Gynecology and Obstetrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00404-020-05618-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00404-020-05618-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00404-020-05618-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T09:55:51Z","timestamp":1666778151000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00404-020-05618-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,4]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["5618"],"URL":"https:\/\/doi.org\/10.1007\/s00404-020-05618-y","relation":{},"ISSN":["0932-0067","1432-0711"],"issn-type":[{"value":"0932-0067","type":"print"},{"value":"1432-0711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,4]]},"assertion":[{"value":"22 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Sandra Wienzek-Lischka declares that she has no conflict of interest. Angelika Sawazki declares that she has no conflict of interest. Harald Ehrhardt declares that he has no conflict of interest. Ulrich J. Sachs declares that he has no conflict of interest. Roland Axt-Fliedner declares that he has no conflict of interest. Gregor Bein declares that he has no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The Ethical Committee of the Medical Faculty of the Justus-Liebig-University, Giessen, Germany, approved this retrospective study on 21th April 2017 (Votum No. 63\/17).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Our retrospective study based on data of medical records and requires only the approval of the Ethical Committee of the Medical Faculty and no informed consent.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}